Vitamin D for Pneumonia

Vitamin D correction reduces acute respiratory infection risk modestly, and only in people who were deficient. It is not a treatment for established pneumonia.

Overview

Vitamin D correction reduces acute respiratory infection risk modestly, and only in people who were deficient. It is not a treatment for established pneumonia.

Verdict

Mixed evidence

Worth correcting a documented deficiency for general respiratory protection; not a pneumonia therapy.

How It Works

Vitamin D supports antimicrobial peptide expression (cathelicidin, defensins) in respiratory epithelium and modulates the inflammatory response to infection.

Dosing & Protocol

Typical dose

Recommended dose: 1000-2000 IU daily if deficient; retest after 3 months
Expected timeframe: Repletion of a deficient level takes 8-12 weeks; any protective effect is preventive, not acute.

Protocol

form: D3, daily dosing
notes: Avoid high-dose bolus regimens
duration: Ongoing if exposure is low
titration: Guided by 25(OH)D retest
starting dose: 1000-2000 IU daily

Evidence

What the studies say

The 2021 individual participant data meta-analysis of 43 randomised trials found daily supplementation reduced the odds of at least one acute respiratory infection modestly, with the effect concentrated in participants with baseline 25(OH)D below 25 nmol/L. Trials of high-dose bolus vitamin D as adjunctive treatment in hospitalised pneumonia have not shown mortality or length-of-stay benefit. The distinction between deficiency correction (small preventive effect) and therapy (no effect) is consistent across the literature.

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Score: 9/10

2017

meta_analysis

n=11321

Martineau AR, Jolliffe DA, Hooper RL +3 more

Vitamin D reduced acute respiratory infection risk overall, with the largest benefit in deficient participants

View source

Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial

Score: 8/10

2014

rct

n=475

Amrein K, et al.

Among critically ill patients with vitamin D deficiency, administration of high-dose vitamin D3 compared with placebo did not reduce hospital length of stay, hospital mortality, or 6-month mortality.

View source

Safety

Caveats

Bolus dosing of 100,000 IU or more has performed worse than daily dosing in trials. Excessive long-term dosing risks hypercalcaemia.

Less likely to help if

People already vitamin D replete gain nothing.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.